Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Trade Blogg Ideas Inter Alia -- Ignore unavailable to you. Want to Upgrade?

To: Rutgers who wrote (219)	5/15/2006 4:57:46 PM
From: Rutgers	Respond to of 285

CYTR Trade Alert Closed this position over the last week at $1.40-1.22. This one ran-up nicely in March, but has been in a steep decline ever since. So, I cut it loose and took a small profit. You can't go broke taking profits?...well, you can't get rich either. Responding ToMessage #219 from Rutgers at 3/31/2006 4:52:27 PM CYTR - Update- set a new 52 week high today and news after the bell... Note to self: Friday news after the bell is generally thought to be bad, but this looks like excellent news...we'll have to wait until Monday to see for sure, but initial reaction in AH is positive... CytRx Reports 2005 Fourth Quarter Financial Results Friday March 31, 4:31 pm ET LOS ANGELES--(BUSINESS WIRE)--March 31, 2006--CytRx Corporation (Nasdaq:CYTR - News), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2005. biz.yahoo.com I am delighted to report that our achievements during the past year have brought us closer to our goal of commercializing human therapeutics based on our small molecule 'molecular chaperone' co-induction technology," said CytRx President and CEO Steven A. Kriegsman. "Most notable among our achievements in 2005 was the advancement of our orally-available small molecule drug candidate arimoclomol into Phase II development for the treatment of amyotrophic lateral sclerosis, also know as ALS or Lou Gehrig's disease. "We also made excellent progress in our HIV vaccine program. Interim results from a Phase I trial indicate our novel DNA + protein vaccine is the first to produce potent antibody responses with neutralizing activity against multiple HIV viral strains, and we expect to announce final results from this trial next quarter," Mr. Kriegsman added. Responding To Message #190 from Rutgers at 3/3/2006 9:32:11 AM CYTR - Update- CytRx Enters Into Agreement for $13.4 Million Private Placement Friday March 3, 8:30 am ET LOS ANGELES, March 3 /PRNewswire-FirstCall/ -- CytRx Corporation (Nasdaq: CYTR - News), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that it has entered into definitive agreements with a group of institutional investors to raise approximately $13.4 million from the private sale of common stock and warrants for the purchase of common stock, with net proceeds to CytRx of approximately $12.4 million after deduction of offering expenses. Under the terms of the financing, CytRx will sell 10.65 million shares of common stock at $1.26 per share and issue warrants to purchase approximately 5.33 million shares of common stock at an exercise price of $1.54 per share. Responding To Message #175 from Rutgers at 2/3/2006 6:51:50 PM Trade Alert and EDGR comment - took a starter position in CYTR today ... ~ $1.20. Stock has trended up recently and it appears that they may have one or more solutions for obesity and diabetes. Having said that, this was near the upper edge of the trend, which is not the best time to initiate a position. Indeed, my custom min.- req't - limit- order filled in a nano-second, which is usually a very good indication of a stock that is about to head down. Of course, I would like to purchase more, so, like EDGR, it would be fine with me if this thing headed back towards the bottom of its recent range. Speaking of EDGR, that was some week after they announced the deal with Donnelly. Of course, it sure looks like it is ripe for some profit taking although the OBV has been excellent so far this year. HT: Allan and Ilene for the DD on CYTR